CTAP (TFA)

CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC50 of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction[1][2].

C51H69N13O11S2.xC2HF3O2

O=C([C@@H](NC([C@H](CSSC(C)([C@H](NC([C@](NC([C@@H](NC1=O)CCCNC(N)=N)=O)([H])[C@H](O)C)=O)C(N[C@H](C(N)=O)[C@H](O)C)=O)C)NC([C@H](N)CC2=CC=CC=C2)=O)=O)CC3=CC=C(C=C3)O)N[C@@H]1CC4=CNC5=CC=CC=C45.OC(C(F)(F)F)=O.[x]

Opioid Receptor

δ Opioid Receptor/DOR; μ Opioid Receptor/MOR

99.6

H2O : 100 mg/mL (ultrasonic)

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)

Blue Ice